Artificial discs are experiencing a cooling trend owing to an expected reduction in CMS reimbursement for both cervical and lumbar disc replacement. Many motion preservation companies are reaching critical regulatory milestones that will likely require a step-up in funding to conduct the large scale clinical studies needed to gain PMA approval. Today, companies in this sector are faced with the troubling task of either scaling back R&D programs to conserve cash or raising additional capital to take the next steps.
by Sharon O’Reilly
With artificial discs experiencing a cooling trend owing to an expected reduction in CMS reimbursement for both cervical and lumbar disc replacement, the spotlight on spine arthroplasty among investors is...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
